Clinical trials: Buprenorphine
Heroin Dependence, Opioid-Related Disorders
A Laboratory Model for Heroin Abuse Medications - 8
The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."
- Conditions
- Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
- Trial name
- NCT00000273
- Testing
- opiates
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- New York State Psychiatric Institute
Food Security
Food Insecurity and Eating Behavior Among Adults Receiving Buprenorphine or Methadone Maintenance Treatment: Pilot Study 2
The goal of this study is to evaluate the effects of a novel, mail-based meal delivery intervention among individuals receiving MOUD on household food security status.
- Trial name
- NCT07251283
- Testing
- NE + Meal Delivery (NE+MD) intervention
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Vermont
Cancer-Related Pain
Buprenorphine for Cancer Pain
This study will evaluate patients on both buprenorphine and full agonist opioids (FAO) to assess for withdrawal symptoms. Patients will be evaluated by clinicians and using validated tools to assess for pain and withdrawal.
- Trial name
- NCT05910190
- Testing
- Use of buprenorphine with FAO > 30 OME, CPM Rx application use
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Fox Chase Cancer Center
Neonatal Abstinence Syndrome
Buprenorphine for Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines
The opioid neonatal abstinence syndrome (NAS) is a condition of withdrawal symptoms after utero exposure to opioids. Sublingual buprenorphine shows promise as a new treatment in NAS.
- Trial name
- MOPPlus (NCT01671410)
- Testing
- oral morphine, sublingual buprenorphine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Thomas Jefferson University
Opioid-Related Disorders
Safety and Tolerability of Buprenorphine/Naloxone Film Strips
This study will evaluate the safety and tolerability on the oral mucosa of buprenorphine/naloxone film strips administered either sublingually or buccally daily for 12 weeks in opioid dependent individuals who are already on a…
- Trial name
- NCT00640835
- Testing
- Buprenorphine/naloxone Film Strip
- Where
- 3 sites in United States
- Volunteers
- 382 people
- Sponsor
- Indivior Inc.
Chronic Pain
Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain
Aim of this project is to customize the choice of the strong opioid in the treatment of cancer chronic pain through the identification of patient clinical history and pain characteristics, moreover in the analysis the…
- Trial name
- NCT00916890
- Testing
- Morphine, Oxycodone, Fentanyl
- Where
- 6 sites in Italy
- Volunteers
- 320 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Major Depressive Disorder
Opiate Suicide Study in Patients With Major Depression
To explore whether intravenous ketamine followed by buprenorphine produces more rapid and sustained anti-suicidal effects than ketamine followed by placebo, investigators will conduct a single study that will take approximately…
- Trial name
- AFSP (NCT04116528)
- Testing
- Buprenorphine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Stanford University
Opioid Use
Buprenorphine for Probationers and Parolees: Bridging the Gap Into Treatment
This five-year study will evaluate the effectiveness of the administration of buprenorphine bridge treatment (BBT) to probationers and parolees compared to treatment as usual (TAU), which consists of referral to a community…
- Trial name
- NCT03616236
- Testing
- Buprenorphine/Naloxone, Treatment as usual
- Where
- United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- Friends Research Institute, Inc.
Pain, Pharmacokinetics
Clinical Study in Healthy Men to Investigate the Uptake of Buprenorphine and Its Elimination From the Body After Dermal Application as Patches for 96 Hours and for 72 Hours
The purpose of the study was to investigate the pharmacokinetics (i.e. the uptake, distribution and elimination from the body) of dermally applied buprenorphine during and after different application periods, i.e., a 96-hour and…
- Trial name
- NCT03770234
- Testing
- Transtec 35 µg/hour transdermal patch
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Postoperative Pain
Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement
The objectives in this study are to evaluate: (1) efficacy of buprenorphine transdermal system (BTDS, Butrans™) on postoperative pain following total knee replacement surgery; (2) the impact of BTDS on functional rehabilitative…
- Trial name
- NCT00403234
- Testing
- Buprenorphine transdermal patch
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Purdue Pharma LP
Opioid-Related Disorders, Substance-Related Disorders
Buprenorphine Maintenance for Opiate Dependence - 6
The purpose of this study is to determine the efficacy of buprenorphine as a substitution pharmacotherapy for opiate dependence.
- Trial name
- NCT00000357
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-use Disorder
Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology
This study will assesses the efficacy of buprenorphine/naloxone vs buprenorphine on maternal withdrawal symptoms and drug cravings.
- Trial name
- NCT03740243
- Testing
- Buprenorphine/naloxone, Buprenorphine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Stony Brook University
Opioid Dependence
Usability of Zubsolv Sublingual Tablets 5.7/1.4 to Suboxone Sublingual Film 8/2 In Buprenorphine/Naloxone Treated Opioid Dependent Population
The primary objective of this study is to compare overall patient preference for either Suboxone® sublingual film 8/2 or Zubsolv® sublingual tablets 5.7/1.4.
- Trial name
- NCT02038790
- Testing
- Suboxone Sublingual Film, Zubsolv sublingual tablets
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Indivior Inc.
Opioid-Related Disorders, Drug Addiction
Medication Treatment for Opioid Use Disorder in Expectant Mothers
The primary objective of this study is to evaluate the impact of treating opioid use disorder (OUD) in pregnant women with extended-release buprenorphine (BUP-XR), compared to sublingual buprenorphine (BUP-SL), on mother and…
- Conditions
- Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse
- Trial name
- MOMs (NCT03918850)
- Testing
- Buprenorphine Injection, Buprenorphine Sublingual Product
- Where
- 12 sites in United States
- Volunteers
- 140 people
- Sponsor
- T. John Winhusen, PhD
Opioid-Related Disorders
Suboxone: (Buprenorphine/Naloxone) Comparison of Two Taper Schedules - 1
The purpose of this protocol is to to compare the clinical utility of two dosage tapering regimens in Buprenorphine/Naloxone stabilized subjects for opiate detoxification.
- Trial name
- NCT00078117
- Testing
- Buprenorphine
- Where
- 11 sites in United States
- Volunteers
- 516 people
- Sponsor
- University of California, Los Angeles
Neonatal Abstinence Syndrome, Neonatal Withdrawal Syndrome
Comparison of Buprenorphine to Morphine in Treatment of Neonatal Abstinence Syndrome (NAS)
The purpose of the study is to determine whether buprenorphine is a beneficial, safe, cost effective treatment alternative to morphine sulfate in the treatment of Neonatal Abstinence Syndrome (NAS).
- Trial name
- NCT01708707
- Testing
- Buprenorphine, Morphine Sulfate
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Pediatrix
Opioid-Related Disorders
Buprenorphine Dosing Interval - 5
The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.
- Trial name
- NCT00000209
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid-Related Disorders, Substance-Related Disorders
Effects of Buprenorphine and Naloxone in Opiate Addicts - 4
The purpose of this study is to evaluate the behavioral and physiological effects of buprenorphine and naloxone, both alone and in combination.
- Trial name
- NCT00000355
- Testing
- Buprenorphine
- Where
- United States
- Sponsor
- National Institute on Drug Abuse (NIDA)
Opioid Use Disorder, Opioid Overdose
A Bundled Intervention to End Opioid Overdoses
Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge.
- Trial name
- B-CARE (NCT07485335)
- Testing
- Bundled intervention (Experimental), control group, Buprenorphine (Experimental)
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- University of Alabama at Birmingham
Opioid Use Disorder
Expanding the Youth Opioid Recovery Support (YORS) Intervention for MOUD Adherence to Adolescents With OUD
Despite rising rates of fatal opioid overdoses in the United States, adolescents with OUD are far less likely than adults to receive and be retained on medication for opioid use disorder (MOUD).
- Trial name
- YORS (NCT06774248)
- Testing
- Youth Opioid Recovery Support (YORS)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Potomac Health Foundations